Adocia SA, a biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today positive preliminary results of a Phase 1b study of M1Pram (“ADO09”), a ready-to-use, fixed ratio co-formulation of pramlintide (Symlin®, AstraZeneca), the only FDA-approved analog of amylin, and A21G human insulin analog (“M1”), a mealtime insulin with a similar time-action profile to human insulin and also the main circulating metabolite of insulin glargine.